Molecular Vision 2011; 17:939-948 <>
Received 17 December 2011 | Accepted 5 April 2011 | Published 15 April 2011

Screening of TYR, OCA2, GPR143, and MC1R in patients with congenital nystagmus, macular hypoplasia, and fundus hypopigmentation indicating albinism

Markus N. Preising,1,2 Hedwig Forster,1 Miriam Gonser,1 Birgit Lorenz1,2

1Department of Paediatric Ophthalmology, Strabismology, and Ophthalmogenetics, University Medical Centre, University of Regensburg, Regensburg, Germany; 2Department of Ophthalmology, Justus-Liebig-University Giessen, Universitaetsklinikum Giessen and Marburg GmbH, Giessen Campus, Giessen, German

Correspondence to: Dr. Markus N. Preising, Laboratory for Molecular Ophthalmology, Justus-Liebig-University Giessen, Department of Ophthalmology, Universitaetsklinikum Giessen and Marburg GmbH, Giessen Campus, Friedrichstr, 18, 35392 Giessen, Germany; Phone: 49-641-99-43837; FAX: 49-641-99-43999; email:

Miss Gonser is now affiliated with the Dental Care Unit Ingolstadt, Ingolstadt, Germany.

Dr. Forster is now in Private Practice, 93138 Lappersdorf, Germany.


Background: A broad spectrum of pigmentation of the skin and hair is found among patients diagnosed with ocular albinism (OA) and oculocutaneous albinism (OCA). Even though complexion is variable, three ocular features, i.e., hypopigmentation of the fundus, hypoplasia of the macula, and nystagmus, are classical pathological findings in these patients. We screened 172 index patients with a clinical diagnosis of OA or OCA based on the classical findings, to evaluate the frequency of sequence variants in tyrosinase (TYR), P-gene, P-protein (OCA2), and the G-protein-coupled receptor 143 gene, OA1 (GPR143). In addition, we investigated the association of sequence variants in the melanocortin receptor 1 gene (MC1R) and OCA2.

Methods: Pigmentation of the hair, skin, iris, and fundus were included in the evaluation of OCA and OA. Male OA patients showing X-linked inheritance were screened for GPR143. Females showing OA without family history were regarded as representing autosomal recessive OA (OA3). Direct sequencing was applied to PCR products showing aberrant single-strand conformation polymorphism–banding patterns.

Results: Fifty-seven male index patients were screened for OA. We identified 16 potentially pathogenic sequence variations in GPR143 (10 novel) in 22 males. In TYR, we identified 23 (7 novel), and in OCA2 28 (11 novel) possibly pathogenic variants. Variants on both alleles were identified in TYR or OCA2 in 29/79 OCA patients and 14/71 OA patients. Sequence changes in TYR were identified almost exclusively in OCA patients, while sequence changes in OCA2 occurred in OCA and OA patients. MC1R sequencing was performed in 47 patients carrying mutations in OCA2 and revealed MC1R mutations in 42 of them.

Conclusions: TYR gene mutations have a more severe effect on pigmentation than mutations in OCA2 and the GPR143 gene. Nevertheless, mutations in these genes affect the development of visual function either directly or by interaction with other genes like MC1R, which can be deduced from a frequent association of MC1R variants with p.R305W or p.R419Q in OCA2.


Albinism is a recessively inherited disease of disturbed melanin synthesis and/or melanin distribution in the epidermis, scalp, uvea, and retinal pigment epithelium. Melanocytes are the site of melanin synthesis, where black-brown eumelanin (found in eumelanosomes) and red-brown pheomelanin (in pheomelanosomes) can be distinguished. Eumelanin and pheomelanin production shares a common pathway, with L-3,4-dihydroxyphenylalanine (L-DOPA) being a common precursor.

In albinism, melanocytes fail to synthesize or distribute melanins properly, which results in oculocutaneous albinism (OCA) presenting with absent or reduced tanning, white, blond, or red-blond scalp, blue irides, and hypopigmented fundi due to a lack of pigments in the skin, hair, and eyes. Autosomal recessive ocular albinism (OA) and X-linked OA present respectively with hypopigmented retinal pigment epithelium and iris pigment epithelial cells only [1]. Albinism is an obvious condition in dark-pigmented populations. However, light complexion, blond hair, and blue irides are features frequent among nonalbinotic individuals in a population like that of Northern Europe, thus compromising their significance when it comes to a diagnosis of albinism. The classical ocular signs of albinism (nystagmus, macular hypoplasia, and hypopigmentation of the fundus) are more reliable in identifying patients with albinism, as they are more specific.

Five genes are currently known to be involved in the etiology of various nonsyndromic forms of albinism. Tyrosinase (TYR; OMIM 606933) and tyrosinase-related protein (TYRP1; OMIM 115501) catalyze the initial steps to melanin production, while P-protein (OCA2; OMIM 611409) and the solute carrier 45 subunit A2 (SLC45A2; OMIM 606202) are transporters localized in the melanosome membrane. Variants in TYR [2], OCA2 [3], TYRP1 [4], and SLC45A2 [5] underlie autosomal recessive OCA (OMIM 203200, 606952, 203100, 203290, 606574, and autosomal recessive OA (OA3) is caused by hypomorphic variants in OCA2 [6]. Several reports of an association of TYR variants with OA3 [7-9] have appeared, but these findings were not confirmed in a recent study on the p.R402Q variant in TYR [10]. X-linked OA (OA1; OMIM 300808) is caused by variants in GPR143; OMIM 300500 [11], a transmembrane receptor in melanocytes of unknown function [11].

Eumelanosomes develop upon activation of the α-melanocyte-stimulating hormone receptor (MC1R; OMIM 155555) by α-melanocyte-stimulating hormone in response to ultraviolet light [12]. Mutant MC1R impairs eumelanosome development and supports pheomelanosome development, resulting in red hair and pale skin phenotypes [13,14].

The exact disease mechanism leading to nystagmus, macular hypoplasia, and optic nerve misrouting in albinism is still unknown. TYR, OCA2, and SLC45A2 are involved in melanin production, but it is unknown how they contribute to the development of the retina and the visual system. Recent data indicate that L-DOPA may be a ligand for the protein encoded by GPR143 [15]. L-DOPA is a precursor in melanin synthesis that has been considered as an antimitogenic factor in cell cycle regulation, playing a crucial role in the maturation of the retina and the optic nerve [16,17].

Recent results by King et al. [18] indicate that MC1R variants in combination with OCA2 variants may lead to persistent red hair color (RHC) in OCA2 patients after birth. Interestingly, MC1R variants alone are insufficient to cause reduced visual functions in red-haired probands, as shown in many studies on the involvement of MC1R variants in RHC [19,20]. These observations may be taken to indicate that early products of the melanin pathway up to DOPA quinone underlie the abnormal neuronal development and reduced visual function in albinism. In this regard, it is unclear if it is a problem of production or distribution of neuroactive components.

In this study, we screened 172 patients with classical ocular signs of albinism (nystagmus, macular hypoplasia, and hypopigmentation of the fundus) for sequence variants in TYR, OCA2, GPR143, and MC1R. Here, we describe the prevalence of sequence variants of the analyzed genes in different albinism phenotypes and report a set of novel sequence variants. We also show that OCA2 sequence variants p.R305W and p.R419Q are more often combined with sequence variants in MC1R than would be expected from the current literature.


This study was approved by the ethical review boards of the Medical Center of the University of Regensburg and the Medical Faculty of the Justus-Liebig-University Giessen, Germany. Informed consent was obtained from all probands or parents according to the Declaration of Helsinki.

DNA samples were collected between 1998 and 2008

One hundred and seventy-two index patients with nystagmus, hypopigmentation of the fundus, and macular hypoplasia were screened. One hundred and forty-two were of Caucasian origin from Germany or Austria. Ten patients were from Turkey, four from Italy, and single patients were from the Balkan States, Africa, Asia, and the USA. Seventy-nine index patients were diagnosed with OCA and 83 index patients with OA. Fifty-seven index patients with OA were male. Additional clinical data were available for 114 out of 172 patients (57 OCA, 57 OA).

Seventy-eight patients were referred for genetic analysis by external physicians and human geneticists. Ninety-four patients were examined by the authors at the Department of Paediatric Ophthalmology, Strabismology, and Ophthalmogenetics at the Medical Centre of the University of Regensburg (1998 to 7/2007) or the Department of Ophthalmology at the Universitaetsklinikum Giessen and Marburg GmbH, Giessen Campus (from 8/2007 onwards). The clinical examination of the patients included visual acuity, refraction, iris translucency, fundus appearance, and glare sensitivity. In selected patients, testing of the albinism-specific crossing of nerve fibers was performed by visually evoked potentials (VEP) [21]. Nystagmus, ocular hypopigmentation, macular hypoplasia, and pedigree information were used as criteria for further clinical examinations [22]. Differentiation between OA and OCA was attempted by recording skin tanning and hair color.

The mean refractive error was computed based on the spherical equivalent calculated from measurements of sphere and cylinder values (sphere - 0.5 cylinder=spherical equivalent). Subsequently, a mean value was computed for each group of patients (OCA, OA1, OA3).

DNA was extracted from peripheral blood lymphocytes and isolated according to Miller et al. [23]. The coding exons of OCA2 (GenBank: NG_009846.1, NM_000275.2) and GPR143 (GenBank: Z48804, NM_000273.2), including adjacent noncoding and flanking sequences, were amplified by PCR using oligonucleotides according to Lee et al. [24] and Schiaffino et al. [25]. Oligonucleotides for TYR (GenBank: M27160, NM_000372) were redesigned to improve access to single-strand conformation polymorphism (SSCP) analysis (Table 1). MC1R (GenBank: NG_012026) was amplified and directly sequenced using oligonucleotides designed as described in Table 1. Except for MC1R, oligonucleotides used for PCR were also used for sequencing.

SSCP analysis was performed using nondenaturing PAGE (PAGE) [26] on Multigel-Long and Maxigel chambers (Biometra Whatman, Göttingen, Germany) at 10 °C. Two types of gels were applied: 8% polyacrylamide and 10% polyacrylamide in 1x TBE buffer. Ten percent polyacrylamide gels were overlaid with a 6% polyacrylamide gel in 1x TBE. Both types of polyacrylamide gels were used with and without a glycerin content of 5%. PCR products showing aberrantly migrating bands in SSCP were submitted to direct sequencing (Seqlab, Göttingen, Germany).

The sequence changes found were confirmed by restriction enzyme digestion whenever an RFLP was created, or by noncoding strand sequencing.

If available, both parents and additional family members were tested for the identified variants in TYR and OCA2, either by direct sequencing or restriction enzyme digestion. Mothers and relatives at risk of males presenting with GPR143 variants were tested for their carrier state. MC1R variants were tested in available relatives of patients with identified OCA2 sequence variants to evaluate their association with MC1R variants.

Missense variants were assessed on the PolyPhen server (June 2009) and SIFT server (June 2009). Splice site and intronic variants were assessed using the Human Splicing Finder server (June 2009). The Predict Protein Server (June 2009) and the PHYRE server (July 2009) were used for secondary structure prediction to evaluate the functional impact of some OCA2 variants.


Patients and clinical data

Hypopigmentation of the fundus was seen in all patients. The extent of fundus hypopigmentation went along with iris translucency findings. Findings for iris translucency were obtained in 114 patients. Mild iris translucency with only a few widely distributed spots was seen in 19/41 of the patients without the identification of an underlying variant in the genes screened. No or only light iris translucency was described in 50% of OCA patients, while obvious or full iris translucency was seen in 25% of patients diagnosed with the OA1 or OA3 sequence variant. A general correlation between positive variant identification and the intensity of iris translucency could not be found.

Visual acuity was measured at logMAR>2.0 in the first months of age and at logMAR 0.22 in childhood (mean 0.6, Figure 1). Refraction was generally hypermetropic. OCA patients with identified variants (29 patients) presented with a mean refractive error of +1 D (range −7.5 D to 10 D), OA1 patients (14 patients) with a mean refractive error of +0.6 D (range −18 D to +9.4 D), and patients with OA3 (18 patients) with a mean refractive error of +1.9 D (range −1 to +2.5 D, Figure 2).

Comprehensive data for skin, hair, and eye color were available for 21 out of 106 patients with a positive variant detection in at least one allele of TYR, OCA2, or GPR143.

Sequence variants in X-linked ocular albinism (OA1)

Screening for sequence variants in GPR143 was performed in 57 male patients with OA (Table 2). Ten of the patients had a positive family history for X-linked inheritance. Twenty-two male OA patients (39%) carried at least one of 15 nonsynonymous variants in GPR143, including eight novel variants (Appendix 1). The prevalence of GPR143 variants increased to full coverage when X-linked inheritance could be ascertained. Six of the 15 identified GPR143 variants were missense variants. A second variant (p.I276V) occurred on the same allele in 2 out of 5 index patients with p.G312V. The remaining nine variants in GPR143 caused premature stop codons either by nonsense variants (2 patients) or frameshifting variants (7 patients, Appendix 1 and Appendix 2).

Sequence variants in autosomal recessive oculocutaneous albinism

Seventy-nine patients diagnosed with OCA were screened for variants in TYR and OCA2. In these patients, we identified 23 nonsynonymous variants in TYR (7 novel, Appendix 1), and 28 variants in OCA2 (11 novel, Appendix 1). TYR variants on both alleles were identified in nine patients (11%) with OCA (Table 2 and Appendix 2). Single heterozygous conditions in TYR and OCA2 were identified in 23 patients (Appendix 1 and Appendix 2) with OCA (30%). The majority of TYR and OCA2 sequence changes altering the amino acid sequence in this study were missense variants (83% in TYR and 79% in OCA2). Four variants in TYR and OCA2 each predicted a preterm translation stop; 2 of 7 novel missense variants in TYR were predicted to be nonpathogenic (Appendix 1).

OCA2 variants on both alleles were identified in 20 OCA index patients (25%, Appendix 2). The variant spectrum in OCA2 was broader: Twenty-three of the 28 sequence variations predicting changes in the primary structure of the protein were missense variants. The remaining sequence changes predicted a preterm translation stop by a nonsense variant, a single nucleotide deletion inducing a frameshift, or splice site variants. Two of 11 novel variants in OCA2 were rated nonpathogenic (Appendix 1). Single heterozygous sequence variations were identified in TYR in six patients (8%), and in OCA2 in 17 patients (21%).

Sequence variants in autosomal recessive ocular albinism (OA, OA3)

Thirty-five male OA patients and 36 female OA patients were screened for variants in OCA2 and TYR. Seven of the male OA patients (12% of all OA males screened) showed compound heterozygous variants in OCA2; none were identified in TYR. Among female patients showing OA3 and screened for TYR and OCA2 variants, we identified seven (20%) sequence variants in TYR (2 variants) and OCA2 (5 variants).

p.R402Q was found in the homozygous state twice and in nine compound heterozygous combinations with other TYR gene variants (9.9% in this study, Appendix 2). In our cohort, p.R402Q was equally frequent identified in patients with the OCA phenotype (8 patients) versus OA (10 patients).

Evaluation of sequence variants in MC1R

MC1R variants were identified in 13 of 18 index patients (72%) carrying OCA2 variants p.R305W or p.R419Q in the single heterozygous state, and in 12 of 17 index patients (71%) carrying OCA2 variations p.R305W or p.R419Q as one of the compound heterozygous alleles. The MC1R sequence changes included strong RHC alleles (p.R151C, p.I155T, p.R160W, p.D294H) and weak RHC alleles (p.V60L, p.V92M, p.R163Q) of MC1R (Appendix 1). Testing the available parents for single heterozygous OCA2 variants revealed one unaffected mother (271.2) cosegregating OCA2R305W and MC1RV60L.


We screened 172 patients with clinical signs of albinism for sequence variations in genes most prevalent in human OCA and OA (TYR, OCA2, and GPR143). Congenital nystagmus was the common symptom in all patients, accompanied by fundus hypopigmentation, macular dysplasia, and iris translucency of varying degree.

Sequence variants of GPR143 in X-linked ocular albinism

Variants were identified in only 22 of 57 male patients screened for GPR143, but were represented in 100% of patients with an obvious family history of X-linked inheritance. This observation underlines the importance of a formal genetic workup before molecular genetic analysis. Eight of 35 male patients in which GPR143 variants were excluded by screening were found to carry pathogenic sequence changes in OCA2; these results are discussed below.

As we reported previously [26], nystagmus and macular hypoplasia are the prominent symptoms of OA1 [27]. Therefore, recent reports of GPR143 underlying isolated X-linked congenital nystagmus (NYS6; OMIM 300814) [28-30] should be considered with caution. Other ocular features, though present, may be less prominent, as shown by Liu et al. [30] and our previous study [26], in patients showing stronger pigmentation. The reports by Peng et al. [28] and Zhou et al. [29] did not present sufficient clinical data to evaluate their hypothesis of isolated nystagmus from GPR143 variants. Therefore, male patients with congenital nystagmus are candidates for X-linked OA and need a thorough clinical examination for this condition.

Sequence variants in TYR

The prevalence of disease causing TYR sequence variants on OCA was 11% in this study. This is explained by the predominant diagnostic criteria used for the oculocutaneous patient cohort in this study, leading to a bias toward the OCA2 phenotype. Other studies showed comparable prevalences [31]. The present study also supports the notion that TYR is not frequently involved in OA3 because only 3% of our cohort of OA3 patients presented with pathogenic sequence variants in this gene. In the present study, p.R402Q was predominantly identified in patients showing the OCA phenotype. This observation contrasts with of those of Hutton and Spritz [9], who identified compound heterozygous combinations with p.R402Q predominantly in OA3. Our findings are comparable with data by Grønskov et al. [32], which showed that TYR variants are rare in OA3 patients.

In addition, Oetting et al. [10] identified p.R402Q in the compound heterozygous state with other pathologic variants in unaffected relatives of OA3 patients. We therefore analyzed p.R402Q in unaffected relatives of our patients and identified one unaffected parent carrying p.R402Q in the homozygous state (286.3), thus arguing against a pathogenic effect.

Sequence variants in OCA2

Pathogenic sequence variants in OCA2 were more frequent in our patient cohort than TYR variants (25% versus 11% in OCA, 17% versus 3% in OA3). These findings suggest that mutations in additional genes remain to be identified in patients fulfilling the selection criteria that were applied in this study.

Two splice site variants were identified in OCA2 that have been known for a long time (Appendix 1). c.1113T>C has been regarded as an isocoding polymorphism (p.G371) at the amino acid level. An evaluation of this variant on the Splice Sequence Finder Server has now demonstrated the gain of a novel splice donor site, which has not been considered before. We identified this variant in two patients, one in the homozygous, and one in the compound heterozygous state, supporting its pathogenicity. Patient 979.1 presented with OCA and was of Turkish origin. The patient carried c.1113T>C in the compound heterozygous state with p.R419Q in OCA2 and p.R160W in MC1R. A Vietnamese OCA patient (2117.2) showed the c.1113T>C variant in the homozygous state. In addition, he carried a second homozygous variant in OCA2 (p.G775S [c.2323G>A]). Evaluation by PolyPhen and SIFT were contradictory; therefore, p.G775S could not be rated pathogenic or nonpathogenic. This subject’s affected mother (2117.1) and father (2117.3) both carried the same combined allele ([c.1113C>T, p.G775S]) heterozygously. The affected mother carried an additional common variant of the Asian population (p.H615R [c.1844A>G]), supporting our interpretation [33].

Six of the nonsynonymous sequence variations in OCA2 were consistently rated as benign by PolyPhen and rated as tolerated by SIFT. Interestingly, three of the variants classified as benign were previously accepted as pathogenic OCA2 variants, including p.V443I, a frequent variant in Caucasians, and p.A481T, a frequent OCA variant in Japanese [34] (Appendix 1). This finding highlights the limitations in predicting the functional consequences of OCA2 variations, which is likely due to the lack of data on their secondary and tertiary structure. The functional and structural prediction of the N-terminal 320 amino acids is insufficient, since only vertebrate sequence data are available for OCA2 in the Entrez Database.

Other frequently encountered sequence variations in OCA2 included p.D257A, p.R305W, and p.R419Q (Appendix 1). p.D257A was identified in the homozygous state in three unaffected relatives in our study, thus arguing against a functional impact.

Evaluations made by PolyPhen and SIFT predicted p.R305W as deleterious or not tolerated (see Appendix 1). Alignments in the Vector NTI 11 suite (AlignX, Invitrogen, Karlsruhe. Germany) using sequence data from various vertebrate species obtained from the Entrez Database showed glutamine to be the predominant amino acid at this position. A single deviation from the rule (arginine) was present in the S. scrofa sequence only. Tryptophan was never present at this position in the sequence data screened. Structural prediction by the PredictProtein Server indicated a decrease in the globularity of the protein by p.R305W. This affects the stability of the β-sheet structure where p.R305 is located.

p.R419Q is positioned within a loop region in the anterior permease domain of the P-protein. The variant is predicted to increase the globularity of the P-protein without any predicted effect on the β-sheet or α-helix formation in this region (PredictProtein Server). The amino acid position is highly conserved among vertebrates.

Several studies have evaluated the influence of p.R305W and p.R419Q on pigmentation [24,35-39]. These studies excluded an influence of both variants on hair color but supported an effect on skin color, since the patients predominantly showed brown hair and light skin complexion.

The reported prevalence of p.R305W in the Northern European population is given at 5%, while p.R419Q is reported at 9% [37]. In this study, we identified p.R305W in 8.4% and p.R419Q in 4.7% of all alleles typed for OCA2 (Appendix 1). p.R305W was predominantly identified in index cases of OCA (9 patients with p.R305W versus 4 patients with p.R419Q of 21 patients carrying two mutant OCA2 alleles) and p.R419Q was predominantly identified in OA3 index cases (4 patients with p.R419Q versus 2 patients with p.R305W of 14 patients carrying two mutant OCA2 alleles). This indicates a yet-unidentified effect of p.R305W and p.R419Q in patients presenting with nystagmus, macular hypoplasia, fundus hypopigmentation, and iris translucency. Pigmentation of the skin and hair used to classify OCA from OA may therefore depend on the compounding variants and possibly on other genes associated with pigmentation.

Influence of MC1R variants

King et al. [18] already reported on p.V443I and other OCA2 variants associated with MC1R variants modifying the OCA2 phenotype. We tested the hypothesis of the association of MC1R variants with OCA2 variants in this study. Combinations of p.V443I and MC1R variants were identified in two patients (810.2 and 1128.1). In addition, we observed a very frequent association of p.R305 W and p.R419Q alleles in OCA2 with sequence changes in MC1R in this study. Presumably, p.R305W and p.R419Q were not considered in previous reports because they were regarded as polymorphisms. A specific disease-related interaction with MC1R has not been excluded so far.

Kanetsky et al. [40] reported MC1R variants in 46.7% of the alleles tested in nonalbino US Caucasians. These probands frequently showed light pigmentation phenotypes in eyes, hair, and skin in double heterozygous as well as single heterozygous patients. A liberal estimation of the allele frequency for any OCA2 sequence variations in albinism patients at about 25% is supported by the literature [32]. Therefore, the coincidence of OCA2 variants and MC1R variants should not exceed 12%–13%, since they are independently inherited. This is far below the frequency of 72% of index patients carrying MC1R variants associated with p.R305W and p.R419Q in a biallelic condition in this study.

All variants in MC1R cosegregating with OCA2R305W or OCA2R419Q despite MC1RV60L were predicted to reside on the cytoplasmic side at the intersections to and from transmembrane domains allowing interaction with the P-protein. MC1RV60L is located on the outside surface of the protein, which limits its potential to interact with the P-protein.

Therefore, we consider p.R305W and p.R419Q to be disease causing alleles, and assume an effect on interaction with MC1R that leads to visual dysfunction. MC1R provides the basis for reduced pigmentation, and P-protein that interacts with MC1R may influence cellular functions necessary for the secretion of growth factors during neural development. Probably, the interaction between MC1R and P-protein does not affect the production of melanin itself, but rather the distribution or production of a precursor like L-DOPA. In this scenario, a minor effect on pigmentation would result in a broad spectrum of pigmentation phenotypes and a low number of patients with reduced visual function and light complexion. Further functional studies will help to clarify the situation.

Appendix 1. Evaluation of the effect of variants identified in this study.

Appendix 2. Index case related summary of the genetic data obtained in this study


We thank all patients and their families for participating, and acknowledge the contribution of 57 colleagues who referred patients included in this study. We wish to acknowledge the excellent technical assistance of Renate Foeckler, Hannelore Falkenstein, and Annabella Janise. We thank Dr. Rainald Schmidt-Kastner (Boca Raton, FL) for critical language review. A part of this data was presented at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology, Ft. Lauderdale.


  1. Sturm RA. Molecular genetics of human pigmentation diversity. Hum Mol Genet. 2009; 18R1:R9-17. [PMID: 19297406]
  2. Giebel LB, Strunk KM, King RA, Hanifin JM, Spritz RA. A frequent tyrosinase gene mutation in classic, tyrosinase- negative (type IA) oculocutaneous albinism. Proc Natl Acad Sci USA. 1990; 87:3255-8. [PMID: 1970634]
  3. Rinchik EM, Bultman SJ, Horsthemke B, Lee ST, Strunk KM, Spritz RA, Avidano KM, Jong MT, Nicholls RD. A gene for the mouse pink-eyed dilution locus and for human type II oculocutaneous albinism. Nature. 1993; 361:72-6. [PMID: 8421497]
  4. Boissy RE, Zhao H, Oetting WS, Austin LM, Wildenberg SC, Boissy YL, Zhao Y, Sturm RA, Hearing VJ, King RA, Nordlund JJ. Mutation in and lack of expression of tyrosinase-related protein- 1 (TRP-1) in melanocytes from an individual with brown oculocutaneous albinism: a new subtype of albinism classified as “OCA3”. Am J Hum Genet. 1996; 58:1145-56. [PMID: 8651291]
  5. Newton JM, Cohen-Barak O, Hagiwara N, Gardner JM, Davisson MT, King RA, Brilliant MH. Mutations in the Human Orthologue of the Mouse underwhite Gene (uw) Underlie a New Form of Oculocutaneous Albinism, OCA4. Am J Hum Genet. 2001; 69:981-8. [PMID: 11574907]
  6. Lee ST, Nicholls RD, Bundey S, Laxova R, Musarella M, Spritz RA. Mutations of the P gene in oculocutaneous albinism, ocular albinism, and Prader-Willi syndrome plus albinism. N Engl J Med. 1994; 330:529-34. [PMID: 8302318]
  7. Fukai K, Holmes SA, Lucchese NJ, Siu VM, Weleber RG, Schnur RE, Spritz RA. Autosomal recessive ocular albinism associated with a functionally significant tyrosinase gene polymorphism. Nat Genet. 1995; 9:92-5. [PMID: 7704033]
  8. Breimer LH, Winder AF, Jay B, Jay M. Initiation codon mutation of the tyrosinase gene as a cause of human albinism. Clin Chim Acta. 1994; 227:17-22. [PMID: 7955413]
  9. Hutton SM, Spritz RA. A comprehensive genetic study of autosomal recessive ocular albinism in Caucasian patients. Invest Ophthalmol Vis Sci. 2008; 49:868-72. [PMID: 18326704]
  10. Oetting WS, Pietsch J, Brott MJ, Savage S, Fryer JP, Summers CG, King RA. The R402Q tyrosinase variant does not cause autosomal recessive ocular albinism. Am J Med Genet A. 2009; 149A:466-9. [PMID: 19208379]
  11. Bassi MT, Schiaffino MV, Renieri A, De Nigris F, Galli L, Bruttini M, Gebbia M, Bergen AA, Lewis RA, Ballabio A. Cloning of the gene for ocular albinism type 1 from the distal short arm of the X chromosome. Nat Genet. 1995; 10:13-9. [PMID: 7647783]
  12. Jimbow K, Park JS, Kato F, Hirosaki K, Toyofuku K, Hua C, Yamashita T. Assembly, target-signaling and intracellular transport of tyrosinase gene family proteins in the initial stage of melanosome biogenesis. Pigment Cell Res. 2000; 13:222-9. [PMID: 10952389]
  13. Healy E, Jordan SA, Budd PS, Suffolk R, Rees JL, Jackson IJ. Functional variation of MC1R alleles from red-haired individuals. Hum Mol Genet. 2001; 10:2397-402. [PMID: 11689486]
  14. Schaffer JV, Bolognia JL. The melanocortin-1 receptor: red hair and beyond. Arch Dermatol. 2001; 137:1477-85. [PMID: 11708951]
  15. Lopez VM, Decatur CL, Stamer WD, Lynch RM, Mckay BS. L-DOPA is an endogenous ligand for OA1. PLoS Biol. 2008; 6:e236 [PMID: 18828673]
  16. Ilia M, Jeffery G. Retinal cell addition and rod production depend on early stages of ocular melanin synthesis. J Comp Neurol. 2000; 420:437-44. [PMID: 10805919]
  17. Ilia M, Jeffery G. Retinal mitosis is regulated by dopa, a melanin precursor that may influence the time at which cells exit the cell cycle: analysis of patterns of cell production in pigmented and albino retinae. J Comp Neurol. 1999; 405:394-405. [PMID: 10076934]
  18. King RA, Willaert RK, Schmidt RM, Pietsch J, Savage S, Brott MJ, Fryer JP, Summers CG, Oetting WS. MC1R Mutations Modify the Classic Phenotype of Oculocutaneous Albinism Type 2 (OCA2). Am J Hum Genet. 2003; 73:638-45. [PMID: 12876664]
  19. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet. 1995; 11:328-30. [PMID: 7581459]
  20. Sturm RA, Duffy DL, Box NF, Newton RA, Shepherd AG, Chen W, Marks LH, Leonard JH, Martin NG. Genetic association and cellular function of MC1R variant alleles in human pigmentation. Ann N Y Acad Sci. 2003; 994:348-58. [PMID: 12851335]
  21. Apkarian P, Shallo-Hoffmann J. VEP projections in congenital nystagmus; VEP asymmetry in albinism: a comparison study. Invest Ophthalmol Vis Sci. 1991; 32:2653-61. [PMID: 1651299]
  22. Lorenz B, Gampe E. Analyse von 180 Patienten mit sensorischem Defektnystagmus (SDN) und kongenitalem idiopathischem Nystagmus (CIN). Klin Monatsbl Augenheilkd. 2001; 218:3-12. [PMID: 11225397]
  23. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988; 16:1215 [PMID: 3344216]
  24. Lee ST, Nicholls RD, Jong MT, Fukai K, Spritz RA. Organization and sequence of the human P gene and identification of a new family of transport proteins. Genomics. 1995; 26:354-63. [PMID: 7601462]
  25. Schiaffino MV, Bassi MT, Galli L, Renieri A, Bruttini M, Denigris F, Bergen AAB, Charles SJ, Yates JRW, Meindl A, Lewis RA, King RA, Ballabio A, De Nigris F, Yates JR. Analysis of the OA1 gene reveals mutations in only one third of patients with X-linked ocular albinism. Hum Mol Genet. 1995; 4:2319-25. [PMID: 8634705]
  26. Preising M. op de Laak JP, Lorenz B. Deletion in the OA1 gene in a family with congenital X linked nystagmus. Br J Ophthalmol. 2001; 85:1098-103. [PMID: 11520764]
  27. O'Donnell FE, , Jr Green WR, Fleischman JA, Hambrick GW. X-linked ocular albinism in Blacks. Ocular albinism cum pigmento. Arch Ophthalmol. 1978; 96:1189-92. [PMID: 666626]
  28. Peng Y, Meng Y, Wang Z, Qin M, Li X, Dian Y, Huang S. A novel GPR143 duplication mutation in a Chinese family with X-linked congenital nystagmus. Mol Vis. 2009; 15:810-4. [PMID: 19390656]
  29. Zhou P, Wang Z, Zhang J, Hu L, Kong X. Identification of a novel GPR143 deletion in a Chinese family with X-linked congenital nystagmus. Mol Vis. 2008; 14:1015-9. [PMID: 18523664]
  30. Liu JY, Ren X, Yang X, Guo T, Yao Q, Li L, Dai X, Zhang M, Wang L, Liu M, Wang QK. Identification of a novel GPR143 mutation in a large Chinese family with congenital nystagmus as the most prominent and consistent manifestation. J Hum Genet. 2007; 52:565-70. [PMID: 17516023]
  31. Zahed L, Zahreddine H, Noureddine B, Rebeiz N, Shakar N, Zalloua P, Haddad F. Molecular basis of oculocutaneous albinism type 1 in Lebanese patients. J Hum Genet. 2005; 50:317-9. [PMID: 15937636]
  32. Grønskov K, Ek J, Sand A, Scheller R, Bygum A, Brixen K, Brondum-Nielsen K, Rosenberg T. Birth prevalence and mutation spectrum in danish patients with autosomal recessive albinism. Invest Ophthalmol Vis Sci. 2009; 50:1058-64. [PMID: 19060277]
  33. Hongyi L, Haiyun W, Hui Z, Qing W, Honglei D, Shu M, Weiying J. Prenatal diagnosis of oculocutaneous albinism type II and novel mutations in two Chinese families. Prenat Diagn. 2007; 27:502-6. [PMID: 17385796]
  34. Kato A, Fukai K, Oiso N, Hosomi N, Saitoh S, Wada T, Shimizu H, Ishii M. A novel P gene missense mutation in a Japanese patient with oculocutaneous albinism type II (OCA2). J Dermatol Sci. 2003; 31:189-92. [PMID: 12727022]
  35. Rebbeck TR, Kanetsky PA, Walker AH, Holmes R, Halpern AC, Schuchter LM, Elder DE, Guerry D. P gene as an inherited biomarker of human eye color. Cancer Epidemiol Biomarkers Prev. 2002; 11:782-4. [PMID: 12163334]
  36. Branicki W, Brudnik U, Kupiec T, Wolanska-Nowak P, Szczerbinska A, Wojas-Pelc A. Association of polymorphic sites in the OCA2 gene with eye colour using the tree scanning method. Ann Hum Genet. 2008; 72:184-92. [PMID: 18093281]
  37. Duffy DL, Montgomery GW, Chen W, Zhao ZZ, Le L, James MR, Hayward NK, Martin NG, Sturm RA. A three-single-nucleotide polymorphism haplotype in intron 1 of OCA2 explains most human eye-color variation. Am J Hum Genet. 2007; 80:241-52. [PMID: 17236130]
  38. Jannot AS, Meziani R, Bertrand G, Gérard B, Descamps V, Archimbaud A, Picard C, Ollivaud L, Basset-Seguin N, Kerob D, Lanternier G, Lebbe C, Saiag P, Crickx B, Clerget-Darpoux F, Grandchamp B, Soufir N, Melan C. Allele variations in the OCA2 gene (pink-eyed-dilution locus) are associated with genetic susceptibility to melanoma. Eur J Hum Genet. 2005; 13:913-20. [PMID: 15889046]
  39. Kerr R, Stevens G, Manga P, Salm S, John P, Haw T, Ramsay M. Identification of P gene mutations in individuals with oculocutaneous albinism in sub-Saharan Africa. Hum Mutat. 2000; 15:166-72. [PMID: 10649493]
  40. Kanetsky PA, Ge F, Najarian D, Swoyer J, Panossian S, Schuchter L, Holmes R, Guerry D, Rebbeck TR. Assessment of polymorphic variants in the melanocortin-1 receptor gene with cutaneous pigmentation using an evolutionary approach. Cancer Epidemiol Biomarkers Prev. 2004; 13:808-19. [PMID: 15159314]
  41. Preising MN, Forster H, Tan H, Lorenz B, de Jong PT, Plomp AS. Mutation analysis in a family with oculocutaneous albinism manifesting in the same generation of three branches. Mol Vis. 2007; 13:1851-5. [PMID: 17960121]
  42. Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities “hand motion” and “counting fingers” can be quantified with the Freiburg Visual Acuity Test. Invest Ophthalmol Vis Sci. 2006; 47:1236-40. [PMID: 16505064]